Apellis Pharmaceuticals Inc (APLS)
29.47
-0.38
(-1.27%)
USD |
NASDAQ |
Sep 27, 16:00
29.47
0.00 (0.00%)
After-Hours: 20:00
Apellis Pharmaceuticals SG&A Expense (Annual): 500.82M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 500.82M |
| December 31, 2022 | 277.16M |
| December 31, 2021 | 176.77M |
| December 31, 2020 | 139.40M |
| December 31, 2019 | 67.05M |
| December 31, 2018 | 22.64M |
| Date | Value |
|---|---|
| December 31, 2017 | 10.46M |
| December 31, 2016 | 4.304M |
| December 31, 2015 | 6.357M |
| December 31, 2014 | 2.908M |
| December 31, 2013 | 1.706M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
67.05M
Minimum
2019
500.82M
Maximum
2023
232.24M
Average
176.77M
Median
2021
SG&A Expense (Annual) Benchmarks
| EyePoint Pharmaceuticals Inc | 51.79M |
| Cassava Sciences Inc | 16.53M |
| Adverum Biotechnologies Inc | 49.92M |
| Rocket Pharmaceuticals Inc | 73.32M |
| Regenxbio Inc | 88.49M |